Cell and Gene Therapy

Refine Search

CRISPR tech worth $21 billion in licensing deals over five years

There has been an uptick in licensing agreements for drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology ove 10 April 2024

Biotechnology

AskBio appoints new chief scientific officer

Asklepios BioPharmaceutical, the wholly-owned but independently operated subsidiary of Bayer, has appointed a new chief scientific officer. 9 April 2024

Biotechnology

Timely added approval for J&J’s Carvykti

8 April 2024

Biotechnology

FDA expands approval for Bristol Myers and 2seventy bio’s Abecma

FDA expands approval for Bristol Myers and 2seventy bio’s Abecma 8 April 2024

Biotechnology

Research shows stellar growth for gene therapies in ophthalmology

Advances in the treatment of ophthalmic conditions with gene therapies have led to a growing market with huge potential for the future, according to research fr 5 April 2024

Biotechnology

UK's MHRA brings in stem cell robot to help develop therapies

4 April 2024

Biotechnology

Serial investor Syncona sees more value in ophthalmic cell therapies

British life science incubator Syncona has launched a new gene therapy company, Beacon Therapeutics, in the ophthalmology space. 4 April 2024

Biotechnology

Ginkgo buys cell therapy assets to broaden technology suite

Cell programming specialist Ginkgo Bioworks has announced the acquisition of the cell therapy platform assets of Modulus Therapeutics, a next-generation immune 2 April 2024

Biotechnology

Data on Adaptimmune's trial with afami-cel published in The Lancet

Data on Adaptimmune's trial with afami-cel published in The Lancet 2 April 2024

Biotechnology

Going private last option for Gamida Cell to remain as going concern

Cell therapy company Gamida Cell will be forced to go private after failing to find a partner for its cell therapy product Omisirge (omidubicel-onlv), which won 28 March 2024

Biotechnology

Red-faced bluebird discloses accounting errors

US biotech bluebird bio revealed that it had made mistakes in previous financial statements in a filing with the US Securities and Exchange Commission. 27 March 2024

Biotechnology

Fiocruz and Caring Cross join forces to produce affordable CAR-T therapy

Fiocruz and Caring Cross join forces to produce affordable CAR-T therapy 27 March 2024

Biotechnology

Venture-backed firm to use artificial intelligence to design proteins

In California, an artificial intelligence-based protein design company called Profluent has added $35 million to its financing, with money being put forward by 25 March 2024

Biotechnology

The week in pharma: action, reaction and insight – week to March 22, 2024

The week in pharma: action, reaction and insight – week to March 22, 2024 25 March 2024

Biotechnology

Biobanking market growth on the way

21 March 2024

Biotechnology

$175 million more in the cap for CAR-T company Capstan

Capstan Therapeutics, a company advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles, has become the latest San Dieg 21 March 2024

Biotechnology

BMS’ Abecma CAR-T therapy gains expanded approval in Europe

BMS’ Abecma CAR-T therapy gains expanded approval in Europe 21 March 2024

Biotechnology

Orchard outlines US launch plans for Lenmeldy, with WAC of $4.25 million

Orchard outlines US launch plans for Lenmeldy, with WAC of $4.25 million 20 March 2024

Biotechnology

Positive regulatory update lifts shares in PTC Therapeutics

American biotech PTC Therapeutics has submitted to the US regulator for approval to market Upstaza (eladocagene exuparvovec). 19 March 2024

Biotechnology

FDA approves first gene therapy for children with MLD

FDA approves first gene therapy for children with MLD 19 March 2024